Mimedx

FNY Investment Advisers LLC’s holdings in MiMedx Group were worth $225,000 at the end of the most recent quarter.

G Medical Innovations has lower revenue, but higher earnings than MiMedx Group.

Goldman Sachs Group Inc. boosted its holdings in MiMedx Group by 40.7% in the 1st quarter.

MiMedx Group (NASDAQ:MDXG) was downgraded by analysts at from a strong-buy rating to a buy rating.

TheStreet upgraded MiMedx Group from a “d” rating to a “c-” rating in a research report on Wednesday, August 2nd.

Fairfield Bush & CO. bought a new position in shares of MiMedx Group during the 2nd quarter worth approximately $51,000.

In addition, MiMedx could eventually benefit from changes to Medicare/Medicaid reimbursement policies.

MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $10.14.

MiMedx’s common stock will continue to trade on the OTC Pink Sheets until market close on the date before listing on the Nasdaq Stock Market under the ticker symbol “MDXG”.

Business Insider sent MiMedx a bunch of additional questions about the investigation.